AstraZeneca Diprivan Anti-Generic Promos Require Corrective Letter - FDA

AstraZeneca must issue a "Dear Healthcare Provider" letter clarifying misleading information regarding generic propofol found in its promotional materials for the anesthetic Diprivan, an FDA warning letter states.